Gabapentinoid Seizure Risks Underscore Need for Medical Detox

Gabapentin and pregabalin are thought of by most people as background medications. They’re not thought of as drugs anyone would need medical detox treatment to stop.

A new study out of Manchester, United Kingdom is a reminder that dependence on them is real. It’s also a reminder that stopping abruptly can trigger seizures and that clinicians managing this withdrawal are doing it without a rulebook.

Researchers reviewed patients admitted for gabapentinoid detoxification at a large regional addiction unit between the year 2017 and 2022. Thirty-eight people in five years is a small number. According to the authors it is also the largest cohort undergoing inpatient gabapentinoid detoxification studied to date.

The paper was published online ahead of print in the Journal of Psychoactive Drugs on June 28, 2026. It was authored by a team from Greater Manchester Mental Health NHS Foundation Trust and the University of Manchester.

Why Medical Detox Matters for Gabapentinoids

Gabapentinoids are the drug class that includes gabapentin and pregabalin. They’re prescribed for nerve pain, seizure disorders and in some countries, generalized anxiety. They are not opioids and they are not benzodiazepines. It is part of why their dependence potential took years to register.

The authors are direct about the current state of play. Gabapentinoids are increasingly implicated in drug-related deaths, little is known about the harms of dependence or about detoxification outcomes and abrupt cessation is associated with adverse events including seizures. Despite that there are no standardized withdrawal scales or treatment regimens in existence.

That absence matters. Clinicians have validated severity scales and established medication protocols for alcohol withdrawal. There are also scored assessments and clear medication pathways for opioid withdrawal. For gabapentinoids, a clinician is improvising against a syndrome that can produce seizures.

What the Study Found

The cohort skewed a particular way. The majority were male, White British and unemployed, with a mean age of 38.9 years and a standard deviation of 8.9 years.

The most clinically significant detail is this, 35 of the 38 patients required detoxification from multiple substances. Gabapentinoid dependence in this sample was almost never a standalone problem.

The majority completed detoxification successfully which is good news in a population this complex. Several factors were significantly associated with an incomplete detoxification.

Relapse during the admission
Complications arising during detoxification
A personality disorder diagnosis
A concurrent benzodiazepine detoxification
A concurrent opioid detoxification

Two things the researchers expected to matter did not. Illicit use of pregabalin was not related to outcome and neither was undergoing multiple concurrent detoxifications. The authors had hypothesized that both would predict worse results.

Polysubstance Detox Is the Real Picture

The finding that concurrent benzodiazepine or opioid detoxification predicted incomplete treatment connects with what withdrawal management typically looks like in practice. Stopping two or three substances at the same time is not two or three separate processes running in parallel.

Symptoms will overlap, medications can interact and the timeline for one substance can collide with the peak of another. Benzodiazepine withdrawal carries a seizure risk on its own.

Combine that with a gabapentinoid taper which also carries a seizure risk and the case for inpatient supervision becomes straightforward.

What This Means for People Seeking Detox

The practical implication is about disclosure and setting rather than about a specific medication. Disclosure first.

Many people do not think to mention a prescribed medication when describing what they use, particularly for one they were originally given by a doctor to manage their pain. An intake assessment that misses a gabapentinoid can produce a taper plan built around the wrong risks.

Setting second. Because no standard protocol exists, the quality of gabapentinoid detox depends heavily on the experience of the team whose coordinating it. Ask whether the program has managed gabapentinoid withdrawal before. Check how it monitors for seizure risk and whether it can handle a simultaneous benzodiazepine or opioid taper if that applies.

Finding Medical Detox

Medical detox for gabapentinoids typically means a medically monitored setting rather than an at-home taper. This is especially the case when other substances are involved. What follows detox matters as much as the detox itself. Relapse during admission was one of the strongest signals of an incomplete course in this study.

Detox.com’s directory lets you filter detox centers by location, level of care, substances treated and insurance accepted. Call 800-996-6135Sponsored to get in contact with a treatment specialist today.